Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EZ - thanks for the LINK link... darn.
Sara : )
eVWAP 157,000 X 2
By: tommy71860 $$$
Reply To: None Tuesday, 26 Jun 2001 at 9:56 AM EDT
Post # of 20118
157,000 X 2- eom
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20116
Bird of Prey,
Then your post as well as my response and the subsequent responses should be deleted from this board as off topic.
I agree completely. Thanks for your posts.
Sara
GNTA news
Genasense(TM) Shown to Be Highly Synergistic With Additional Anticancer Drugs At European Hematology Meeting
BERKELEY HEIGHTS, N.J., Jun 25, 2001 /PRNewswire via COMTEX/ -- Genta Incorporated (Nasdaq: GNTA) announced the presentation of two scientific studies that documented the synergy between Genta's lead antisense compound, Genasense(TM), with drugs that are used in the Company's ongoing, late-stage, clinical trials in patients with both multiple myeloma and acute myeloid leukemia. The experimental studies were presented on Saturday and Sunday at the annual meeting of the European Hematology Association in Frankfurt, Germany.
In the first presentation, investigators from the University of Texas-San Antonio showed that Bcl-2 (the target of Genasense(TM)) was a major factor in the resistance of myeloma to standard chemotherapy. Genasense(TM) treatment markedly reduced Bcl-2 levels in myeloma cells. Moreover, Genasense(TM) used in combination with a standard chemotherapy drug (dexamethasone) caused a 3 to 4-fold increase in cell death compared with the use of dexamethasone alone. Genta is currently studying Genasense(TM) combined with dexamethasone in a randomized, multicenter, Phase 3 clinical study in patients with multiple myeloma.
In the second presentation, researchers from the M.D. Anderson Cancer Center in Houston, Texas showed that Genasense(TM) significantly decreased Bcl-2 protein in acute myeloid leukemia (AML) cells by 72 hours. Researchers also showed that the combination of Genasense(TM) plus Mylotarg(R), a monoclonal antibody currently used to treat AML patients, increased cell death up to 63% compared to treatment with Mylotarg(R) alone. Genta is currently evaluating Genasense(TM) combined with Mylotarg in a multicenter trial in patients with this type of leukemia.
Abstracts can be viewed at: http://www.eurocongres.com/eha2001/scientific.html
"These are the first public presentations of data that have strongly supported the scientific rationale for our clinical strategies in both myeloma and AML," said Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "In these studies, Genasense(TM) clearly enhanced the anticancer activity of two distinct drug classes, monoclonal antibodies and steroids. This approach has been adapted for both of our current, late-stage clinical trials in these illnesses."
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The research platform is anchored by oligonucleotide chemistry, particularly applications of antisense technology. Genasense(TM), the Company's lead compound, has received "Fast Track" and "Orphan Drug" designation from the Food and Drug Administration. Genasense(TM) is currently undergoing late-stage, Phase 3 clinical testing. Genta's pipeline also comprises a portfolio of small molecules, including gallium-containing compounds for treatment of diseases associated with accelerated bone loss, Androgenics compounds for prostate cancer, and Decoy Aptamers for broad anticancer use. Genta aims to become a direct marketer of its pharmaceutical products in the United States. For more information about Genta, please visit our website at: http://www.genta.com.
The statements contained in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words "anticipates," "believes," "expects," "intends," "may" and "plans" and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward-looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials, and delays in the initiation or completion of clinical trials may occur as a result of many factors. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations; timely development, receipt of necessary regulatory approvals, and acceptance of new products; the successful application of the Company's technology to produce new products; the obtaining of proprietary protection for any such technology and products; the impact of competitive products and pricing and reimbursement policies; and changing market conditions. The Company does not undertake to update forward- looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37814188
SOURCE Genta Incorporated
CONTACT: Investor Relations of Genta Incorporated, 908-286-3980,
info@genta.com; media inquiries - Brad Miles, 212-477-9007, ext. 17, or
investor inquiries - Jonathan Fassberg, 212-477-9007, ext. 16,
jonathan@troutgroup.com, both of BMC Communications-Trout Group, for Genta
Incorporated
URL: http://www.genta.com
http://www.prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
-0-
KEYWORD: New Jersey
Germany
INDUSTRY KEYWORD: MTC
HEA
BIO
AQSE news today
Monday June 25, 2001 09:11 AM
Company Press Release
SOURCE:Aquasearch, Inc.
Aquasearch to Exhibit at BIO 2001 - International Biotechnology Convention And Exhibition
KAILUA-KONA, Hawaii, June 25 /PRNewswire/ -- Aquasearch, Inc. (OTC Bulletin Board: AQSE), Hawaii's Biotechnology Company of 2000, announced today that it has been selected by the State of Hawaii to exhibit at the world's largest biotechnology convention in San Diego, California from June 24th to June 27th. BIO 2001, the annual meeting of the Biotechnology Industry Organization, is expected to attract 13,000 attendees from biopharmaceutical companies around the world.
"We are very excited that Aquasearch will be exhibiting at BIO 2001," said Mark Huntley, Ph.D., Chief Executive Officer of Aquasearch. "This is an excellent opportunity for us to meet with companies that we have isolated as potential partners for our drug discovery program."
Aquasearch's drug discovery program, which is searching for potential drug candidates derived from microalgae, is centered on its proprietary cultivation technology designed to enable drug discovery from microscopic plants. In January, Aquasearch signed an exclusive agreement with the University of Hawaii to develop new pharmaceuticals from a collection of more than 2,400 strains of microalgae held by the University. The collection has already produced cryptophycin, an anti-cancer drug candidate now in Phase II clinical trials being run by Eli Lilly and Company.
"We believe that Aquasearch's previously announced anti-cancer drug candidate, now under further study by the U.S. National Cancer Institute, and many other compounds we are developing from the University of Hawaii's collection, puts us in a unique position in the biopharmaceutical industry," said Dr. Huntley.
"Most of the companies at this conference are looking to partner with other companies to discover new drugs," he said. "We believe that our exclusive access to over 170 novel -- and bioactive -- compounds from the University of Hawaii's collection makes us an attractive candidate for a collaborative drug development deal with many of the biotechnology companies attending this conference."
"Even though a majority of prescription drugs now on the market were originally derived from plants, the pharmaceutical industry has virtually ignored microalgae as a source of new drugs because sufficient quantities could not be provided for study," said Huntley. "We believe that our technology -- growing microalgae at large scale under controlled conditions -- opens that door. Pharmaceutical companies need to expand their product pipelines. Genomics and proteomics have given the industry powerful tools for the rapid discovery of new drug candidates, but the tools are useless if there are no new chemical structures to look at. We believe our collaboration with the University of Hawaii provides a tremendous opportunity for the industry."
Dr. Huntley will be attending the conference with Dr. Melanie Weaver and Richard L. Sherman. Dr. Weaver, Aquasearch's Director of Clinical Operations, manages the Company's clinical trials. Mr. Sherman is a director of Aquasearch. He is a former deputy general counsel of SmithKline Beckman Corporation, where for 13 years he structured and negotiated major commercial transactions, acquisitions and strategic alliances. He managed SmithKline's legal department and accumulated experience in dealing with companies throughout Europe, Asia, Africa and the former Soviet Union. SmithKline merged in 2000 with Glaxo Wellcome to form GlaxoSmithKline.
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential for the Company's drug discovery program, the outcome of its agreements with the University of Hawaii and the U.S. National Cancer Institute, as well as statements that include the words "believe," "expect," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Aquasearch to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Aquasearch's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2000 and any subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Aquasearch assumes no responsibility to update the information included herein for events occurring after the date hereof.
For further information please contact Andrew Haag, Aquasearch Director of Investor Relations, 866-247-4740 or Jeff Weaver, CEO of Western Financial Communications, 949-574-1191, for Aquasearch.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X44684825
--------------------------------------------------------------------------------
Contact:
Andrew Haag, Director of Investor Relations of Aquasearch,866-247-4740; or Jeff Weaver, CEO of Western Financial Communications,949-574-1191, for Aquasearch
http://www.clearstation.com/cgi-bin/bbs?post_id=2377065&Refer=http://www.clearstation.com/cgi-bi...
eVWAP 26,500 X 2
By: tommy71860 $$$
Reply To: None Monday, 25 Jun 2001 at 9:50 AM EDT
Post # of 20106
26,500 X 2- eom
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20104
xxrayeyes...
Thanks although this seems counter intuitive. I would have though a high ratio was bearish. Or should I think of it like stochastic of oversold?
"A short interest ratio is found in several newspapers and databanks and is a calculation of the latest reported short interest positions for the month divided by the daily average trading volume. A high ratio is considered bullish while a low ratio is considered bearish. A ratio of 2 is considered 2 days potential buying power."
Sara
xxrayeyes,
Could you explain how the short ratio is calculated? tia
Sara
Ended up 12% on nice volume : )
Sara
Thanks for the heads up... looks like today is as good as time as any to add a few more shares.
Sara : )
eVWAP 35,000 X 2
By: tommy71860 $
Reply To: None Friday, 22 Jun 2001 at 10:04 AM EDT
Post # of 20092
35000X2 for today- 1133600X2 for yesterday-eom
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20092
Re: 1,133,500 x 2 was yesterdays volume
by: the_grand_poobah2000
Long-Term Sentiment: Strong Buy 06/22/01 10:16 am
Msg: 121318 of 121320
The young lady at the Phlix made a mistake.....oh well
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
Posted by: baltimoreblue
Date: 6/22/2001 10:03:53 AM (ET)
Post # of 3859
I look at many of the free services
that come across my computer
and without any doubt I feel I have found one of the very best!
Not often do you came across this kind of information.
Now you can make the choice, that is if you sign up!
Hey it’s free and simple.
http://gp9287.ca-homepage.com/
oops... I said oversold and meant overbought, but you must have known what I meant... lol
must be time to call it a night : )
Sara
EZ - Nice find on that PR release explaining all those insider buys. Like the way you stick with something until you have the answer.
Sara : )
Muel, DRUG looks really interesting!
I was looking at the chart and it's really spiking up on that recent news... and I seem to often make the mistake of buying on news and then watching it pull back a bit when the initial excitment is over. And since it looks oversold I might wait and see if it drops back a little before entering... what do you think? Should we ask Reid?
Sara
Welcome back : ) eom
EZ...
Ahhh... yes clicking on it you can then see the details. Thanks for pointing that out.
Sara : )
EZ... is that what that is? How can you tell the difference?
Sara
LINK - flurry of insider trading
http://biz.yahoo.com/t/l/link.html
Sara
Great catch! eom
yesterday's list of trades
by: the_grand_poobah2000
Long-Term Sentiment: Strong Buy 06/21/01 01:54 pm
Msg: 121093 of 121102
Symbol Company
AA ALCOA INC
ABT ABBOTT LAB Y
ADI ANALOG DEVICES,INC.
AIG AMER INTER GRP INC
AOL AMERICA ONLINE
AVP AVON PRODUCTS
BMY BRISTOL MEYERS SQU.
C CITIGROUP
CCL CARNIVAL CORP
DAL DELTA AIRLINES
DD DUPONT DENEMOURS
DIS WALT DISNEY COMP
DUK DUKE ENERGY CORP
EMC EMC CORPORATION
EMR EMERSON ELECTRIC
GE GENERAL ELECTRIC
GLW CORNING INCORP.
IBM INTL. BUS. MACHI
MDT MEDTRONIC INC.
MO PHILIP MORRIS CO
MOT MOTOROLA INC
MRK MERCK & CO. INC.
PFE PFIZER INC.
SFA SCI-ATL INC
SGP SCHERING-PLOUGH
UNH UNITEDHEALTH GROUP
WM WASHINGTON MUTUAL
WMT WAL-MART STORES
1,968,200 shares, executed pre-opening in eVWAP with
complete anonymity, no market impact, at very low fees.
--------------------------------------------------------------------------------
The Company / Affiliates / Leadership / Investor
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
News on AGEN today...
This is another one of my favs
Antigenics Receives Key Patents Expanding Its Immunology Platforms
http://www.clearstation.com/cgi-bin/bbs?post_id=2369828
Chart
http://stockcharts.com/def/servlet/SC.web?c=agen
Business Summary (taken yahoo)
Antigenics, Inc. is developing treatments for cancers, serious infectious diseases, autoimmune disorders and degenerative disorders, using the Company's proprietary technologies to program the immune system and improve quality of life. These products include immunotherapeutics based on a specific class of heat shock proteins (HSPs), which activate powerful cellular immune responses, and Stimulon-based products, including QS-21, which activates superior antibody responses. At year-end 2000, the Company was evaluating its lead HSP-based immunotherapeutic, Oncophage, in an international multi-center Phase III clinical trial in kidney cancer, and in five additional cancer indications in Phase II or Phase I/II trials. Through its internal programs and partnerships, the Company was also testing its Stimulon-based products in 11 Phase III and Phase II clinical trials for cancer, several infectious diseases and degenerative disorders.
Sara
correction, monthly beat old record by 400,000
By: stosh_5 $$$
Reply To: 20060 by stosh_5 $$$ Thursday, 21 Jun 2001 at 11:06 AM EDT
Post # of 20066
My monthly record number was wrong
With 6 trading days to go, we broke the old record by about 400,000 shares, not 200,000. When I looked at the monthly volumes I was thinking I was looking at revenue shares rather than raw volume. Either way it's good, this is just a little better.
Sorry about the mix-up.
Stosh
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20065
Record breaking eVWAP volumes!
By: stosh_5 $$$
Reply To: 20059 by sarals $$$$ Thursday, 21 Jun 2001 at 10:03 AM EDT
Post # of 20060
New daily record by just over 300,000
New weekly record by about 600,000
New monthly record (with 6 trading days to go) by about 200,000
stosh
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20060
eVWAP 2,267,000 X 2 !!!!!!!!!!!!!
By: stosh_5 $$$
Reply To: None Thursday, 21 Jun 2001 at 9:49 AM EDT
Post # of 20057
YEEEEHAAAAA! 2,267,000 x 2 confirmed!
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20057
Updated today: RITTERREISER VS XXXXXXXX
Case Description
Case ID: 010402722
Case Caption: RITTERREISER ETAL VS XXXXXXXX ETAL
Filing Date: Monday , April 23rd, 2001
Court: MN - MAJOR NON JURY
Location: CL - 100 PENN SQUARE EAST
Jury: N - NON JURY
Case Type: E3 - EQUITY - NO REAL ESTATE (TRO)
Status: CLLST - LISTED FOR STATUS CONFERENCE
Related Cases
No related cases were found.
Case Event Schedule
Event Date/Time Room Location Judge
STATUS CONFERENCE 16-JUL-2001
02:00 PM 100 PENN SQUARE EAST CLC - TRIAL LISTING unassigned
Case Parties
Seq # Assoc Expn Date Type ID Name
1 ATTORNEY FOR PLAINTIFF A34414 FRANK, ALAN L
Address: 1835 MARKET ST STE 320
11 PENN CENTER
PHILADELPHIA PA 19103
(215)864-2900 Aliases: none
2 1 PLAINTIFF @4247418 RITTEREISER, FREDERIC
Address: 11 PENN CENTER 1835 MARKET ST
4TH FLOOR
PHILADELPHIA PA 19103 Aliases: none
3 1 PLAINTIFF @4247426 ASHTON TECHNOLOGY GROUP INC
Address: 1835 MARKET ST STE 400
PHILADELPHIA PA 19103 Aliases: none
4 DEFENDANT @4247429 XXXXXXXX, MARY
Address: xxxxxxxxxxxxxx
Aliases: none
Docket Entries
Filing Date/Time Docket Type Filing Party Disposition Amount
23-APR-2001
10:57 AM ACTIV - ACTIVE CASE
Docket Entry: none.
23-APR-2001
11:11 AM CIVIL - COMMENCEMENT OF CIVIL ACTION FRANK, ALAN L
Docket Entry: none.
23-APR-2001
11:11 AM CMPLT - COMPLAINT FILED NOTICE GIVEN FRANK, ALAN L
Docket Entry: COMPLAINT WITH NOTICE TO DEFEND WITHIN TWENTY (20) DAYS AFTER SERVICE IN ACCORDANCE WITH RULE 1018.1 FILED.
23-APR-2001
11:11 AM CLWCM - WAITING TO LIST CASE MGMT CONF FRANK, ALAN L
Docket Entry: none.
11-MAY-2001
02:07 PM CLTMN - TRANSFERRED TO MAJOR NON-JURY SHEPPARD, JR., ALBERT W
Docket Entry: AFTER A REVIEW OF PLAINTIFF'S(S') PLEADING AND THE COMMERCE PROGRAM CASE CRITERIA, IT IS ORDERED THAT THIS CASE IS INAPPROPRIATE FOR THE COMMERCE PROGRAM BECAUSE IT DOES NOT INVOLVE A DISPUTE BETWEEN OR AMONG TWO BUSINESS ENTERPRISES. ADMINISTRATIVE DOCKET 01 OF 1999 IN RE: COMMERCE CASE MANAGEMENT PROGRAM, B.1.2. IT IS FURTHER ORDERED THAT THE CASE IS TRANSFERRED TO THE NON JURY PROGRAM AND PLACED IN A WAITING TO LIST STATUS CONFERENCE STATUS. BY THE COURT....SHEPPARD J 5/11/01
11-MAY-2001
02:10 PM CLNGV - NOTICE GIVEN
Docket Entry: none.
11-MAY-2001
02:10 PM CLWST - WAITING TO LIST STATUS CONF
Docket Entry: none.
14-MAY-2001
03:50 PM REFUN - REFUND OF FEES/PROTHY APPROVED
Docket Entry: $22.00 REFUNDED TO FRANK & ROSEN. OVERPAYMENT.
21-MAY-2001
10:36 AM ENAPP - ENTRY OF APPEARANCE FILED XXXXXX, MARY
Docket Entry: ENTRY OF APPEARANCE OF MARY XXXXX FILED ON BEHALF OF DFT, MARY XXXXXXX (PRO-SE) $102.00 FEE PAID FILED.
29-MAY-2001
03:45 PM PROBJ - PRELIMINARY OBJECTIONS FILED XXXXXX, MARY
Docket Entry: DEFENDANT, MARY XXXXXX PRELIMINARY OBJECTIONS PURSUANT TO PA RCP 1028(A) TO PLAINTIFFS' COMPLAINT.
14-JUN-2001
03:55 PM ANPRO - ANSWER TO PRELIMINARY OBJCTNS FRANK, ALAN L
Docket Entry: ANSWER TO DEFENDANT MARY XXXXXXX' PRELIMINARY OBJECTIONS.
20-JUN-2001
09:23 AM CLLST - LISTED FOR STATUS CONFERENCE
Docket Entry: none.
Reid,
That is good news since I decided to hang onto NVS : )
Sara : )
xxrayeyes,
Notice the trend lines I have drawn. This is what I would like the program to be able to do.
gotcha.
doesn't that make it on topic?
Okay with me : ) ...just didn't want to irritate anyone. It's going to take me a while to build a skeleton, then I'll probably be back with more questions. I plan to do it as a desktop application (i.e. QuoteTracker) unless that's a big problem.
tia
Sara
xxrayeyes,
My first question would be how is it different from this chart. Being a charting novice, could you show me an example of a "close line chart"?
http://www.investorshub.com/boards/read_msg.asp?message_id=130581
Probably we should take this to private messages since it is a bit offtopic. Is that ok?
Sara
xxrayeyes...
It would be nice if someone could just write a program to draw the proper trend lines. I'm pretty sure that could be done but I'm not a programmer.
I am a programmer and looking for a project. If you'd like to work with me giving me the specs, I might be able to do it in my spare time.
Sara : )
eVWAP 984,100 X 2
By: stosh_5 $$$
Reply To: None Wednesday, 20 Jun 2001 at 10:03 AM EDT
Post # of 20050
984,100 x 2 confirmed
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20050
Well said, Joe. eom
Re: Regarding the 300 odd number .....
by: HojichaMan (41/M/Philadelphia, PA) 06/19/01 12:57 pm
Msg: 120530 of 120722
From the original SEC approval of the VWAP system:
When entering Orders or Commitments, Participants will be required
to provide a description of the Order or Commitment, as well as account
identification information needed to determine priority and
eligibility. Participants must provide the following information when
entering an Order or Commitment:
<bullet> Buy/Sell designation;
<bullet> Volume (number of shares). As previously stated, the
minimum size for Commitments is 2,500 shares and the minimum size for
Orders is 5,000 shares. All Commitments and Orders must be entered in
500 share increments;\29---------------------------------------------------------------------------
\29\ The Exchange's Floor Procedures Committee may determine
whether to establish: (i) alternative minimum sizes for Commitments
and Orders; or (ii) alternative minimum increment sizes. Any
adjustments to Order, Commitment, or increment sizes are required to
be based on market and participant need, and are subject to prior
written notice.
Hoji
http://messages.yahoo.com/bbs?action=m&board=4687979&tid=astn&mid=120530&sid=4687979
Thanks Reid,
I saw that blurb and know that they are not a one trick pony... one of my reasons for not wanting to bail out. But I appreciate your analysis that the candles show that the selling is slowing... I really don't want to ride it down.
I double checked a couple places and they did show .58 for P/E
which sure make this look like a great buy.
Sara : )
Tuesdays eVWAP trades
By: johnnyhypen $
Reply To: None Wednesday, 20 Jun 2001 at 12:05 AM EDT
Post # of 20043
Tuesday's eVWAP Trades
17 Trades. 234,300 x 2 Confirmed. TEXACO 1 trade 6300.
2000 AXP
10000 AMR
10000 BAC
7000 BAC
10000 BMY
4000 C
10000 DAL
80000 EMC
50000 EMC
8000 ETR
10000 HIG
10000 MDT
11000 MET
1000 MU
2000 MMM
6300 TX
3000 WM
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20043
Reid,
Okay, here's a classic situation I've found myself in a few times. I bought NVS around 40ish a while back looking long term. Then today bad news comes out and I miss it... and of course, the price of the stock reacts. This is basically a good company and probably won't be that affected by this set back... so my question is... Is it too late to bail out? Do you feel it will bounce back? What should one do in this situation looking long term?
News
http://public.wsj.com/sn/y/SB992880508267385723.html
Chart
http://stockcharts.com/def/servlet/SC.web?c=NVS,uu[m,a]daclyymy[dc][pb50!b200][vc60][iUb14!La12,26,9...
Sara
Links to the eVWAP charts
http://www.geocities.com/mlo23
sorry about the charting fiasco below.
Sara
That'll be great! Thanks.
Sara
It's a lie Mary and you know it. eom